Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy

Table 2

TPP parameters for prioritizing MPT development.

Parameter	Preferred criteria	Minimally acceptable criteria
Indications	HIV + contraception; (high emphasis for sub-Saharan African markets); (high emphasis for sub-Saharan African markets)	HIV + HSV (high emphasis for non-LDC markets); contraception + STI (high emphasis for Indian and Chinese markets); BV, HPV, and TV (moderate emphasis); GC + syphilis (minimal emphasis)
Route of administration	Vaginal rings	Oral pills, injectables
Dosage form and schedule	Sustained release (1–12 months); Pericoital; Fast-acting; Topical (vaginal)	Daily; Oral
Efficacy:
(i) HIV	80%	40%–70%
(ii) Contraception	>Current levels per contraceptive of >90%	Current levels with recommended use
(iii) STI	>80%	40%
Storage conditions	>40°C/75% RH	15–30°C/65% RH for topical/pills; Refrigeration at 4°C for injectables
Shelf life	>36 months	24 months
Yearly product cost/user	<US$ 50	<US$ 100
Disposal/waste	Concealable, biodegradable user disposal	Controlled disposal (to include all associated materials (implant, injectables))
Adherence	>80% of users follow prescribed regimen	>60% of users follow prescribed regimen
Time to licensure	5 years	8–12 years (by 2020)
Reversibility	0–24 hours for oral, topical, sustained-release methods; 14 days for implants, injectables	14–30 days for oral, topical, sustained-release methods; 90 days for implants, injectables